CN101239074B - 海狗油在制备治疗性功能障碍药物中的应用 - Google Patents
海狗油在制备治疗性功能障碍药物中的应用 Download PDFInfo
- Publication number
- CN101239074B CN101239074B CN2008100007607A CN200810000760A CN101239074B CN 101239074 B CN101239074 B CN 101239074B CN 2008100007607 A CN2008100007607 A CN 2008100007607A CN 200810000760 A CN200810000760 A CN 200810000760A CN 101239074 B CN101239074 B CN 101239074B
- Authority
- CN
- China
- Prior art keywords
- adeps phocae
- phocae vitulinae
- epa
- dha
- dpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 208000012201 sexual and gender identity disease Diseases 0.000 title claims abstract description 12
- 208000015891 sexual disease Diseases 0.000 title claims abstract description 12
- 230000032050 esterification Effects 0.000 claims abstract description 29
- 238000005886 esterification reaction Methods 0.000 claims abstract description 29
- 238000000199 molecular distillation Methods 0.000 claims abstract description 19
- -1 polyene unsaturated fatty acid Chemical class 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000004821 distillation Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 238000007872 degassing Methods 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 239000007901 soft capsule Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 238000009834 vaporization Methods 0.000 claims description 4
- 230000008016 vaporization Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 2
- 210000003899 penis Anatomy 0.000 abstract description 27
- 230000001568 sexual effect Effects 0.000 abstract description 10
- 210000002149 gonad Anatomy 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000013011 mating Effects 0.000 abstract description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 5
- 206010047139 Vasoconstriction Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000025033 vasoconstriction Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 35
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 34
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 33
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000036299 sexual function Effects 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 201000001880 Sexual dysfunction Diseases 0.000 description 10
- 231100000872 sexual dysfunction Toxicity 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 230000000916 dilatatory effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- 230000008728 vascular permeability Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 230000027326 copulation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 5
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 5
- 229960000317 yohimbine Drugs 0.000 description 5
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000037111 immune power Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical group 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000021290 n-3 DPA Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | |
EPA | 8.0 | 7.6 | 8.5 | 6.5 | 9.0 |
DHA | 11.5 | 9.5 | 10.6 | 10.5 | 12.5 |
DPA | 4.5 | 4.2 | 7.0 | 4.0 | 8.0 |
组别 | 对照组 | 育亨宾 | 本发明的海狗油胶囊 | |||
剂量 | -- | 2 | 40 | 20 | 10 | |
潜伏期(分钟) | 20° | 4.2±2.2 | 2.4±0.5<sup>**</sup> | 1.2±0.4<sup>***</sup> | 2.6±0.5<sup>**</sup> | 1.6±0.5<sup>***</sup> |
1′ | 5.2±1.5 | 3.4±1.1<sup>***</sup> | 1.8±0.8<sup>***</sup> | 3.0±1.6<sup>***</sup> | 3.0±2.0<sup>**</sup> | |
2′ | 4.8±1.8 | 2.8±1.6<sup>**</sup> | 1.4±0.5<sup>***</sup> | 2.4±1.3<sup>***</sup> | 2.6±1.5<sup>***</sup> | |
扑捉次数 | 20° | 4.5±5.6 | 10.2±6.9<sup>*</sup> | 20.6±9.2<sup>***</sup> | 13.9±11.2<sup>**</sup> | 9.8±9.2<sup>*</sup> |
1′ | 3.1±5.0 | 11.8±9.6<sup>**</sup> | 16.7±9.7<sup>***</sup> | 11.7±8.5<sup>***</sup> | 9.1±9.4<sup>*</sup> | |
2′ | 1.9±3.3 | 6.5±6.7<sup>*</sup> | 9.9±10.6<sup>**</sup> | 11.9±12.3<sup>**</sup> | 5.9±6.6<sup>*</sup> | |
射精次数 | 20° | 3.0±4.1 | 9.8±6.8<sup>**</sup> | 15.2±5.4<sup>***</sup> | 11.4±9.7<sup>**</sup> | 8.0±7.5<sup>*</sup> |
1′ | 2.3±3.8 | 10.1±5.5<sup>***</sup> | 11.5±6.2<sup>***</sup> | 9.6±7.3<sup>**</sup> | 6.6±6.6<sup>*</sup> | |
2′ | 1.8±2.5 | 4.3±3.6<sup>*</sup> | 5.8±5.6<sup>*</sup> | 10.9±12.9<sup>**</sup> | 4.2±6.0<sup>*</sup> |
组别 | 对照组 | 育亨宾 | 本发明的海狗油胶囊 | |||
剂量 | -- | 2 | 40 | 20 | 10 | |
扑捉率(%) | 20′ | 60 | 80 | 100 | 80 | 70 |
1° | 40 | 80 | 90 | 80 | 70 | |
2° | 40 | 70 | 80 | 70 | 60 | |
射精率(%) | 20′ | 50 | 80 | 100 | 80 | 70 |
1° | 40 | 70 | 90 | 80 | 70 | |
2° | 40 | 60 | 80 | 70 | 60 |
对阴茎勃起和勃起维持的自信感 | 能够插入阴道的勃起频度 | 性交时阴茎勃起和勃起维持到性交的频度 | 对阴茎勃起和勃起维持的难度 | 对性生活的满足度 | ||||||
本发明产品(n=28) | 治疗前 | 治疗后 | 治疗前 | 治疗后 | 治疗前 | 治疗后 | 治疗前 | 治疗后 | 治疗前 | 治疗后 |
1.82±0.54 | 3.32±0.39 | 1.89±0.67 | 3.11±0.32 | 1.82±0.65 | 3.18±0.47 | 1.89±0.61 | 3.25±0.47 | 1.79±0.62 | 3.36±0.47 | |
安慰剂(n=28) | 2.04±0.63 | 2.07±0.88 | 2.17±0.97 | 2.18±0.92 | 2.14±0.95 | |||||
P值 | 0.002 | 0.001 | 0.01 | 0.002 | 0.001 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100007607A CN101239074B (zh) | 2007-01-24 | 2008-01-16 | 海狗油在制备治疗性功能障碍药物中的应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710002458 | 2007-01-24 | ||
CN200710002458.0 | 2007-01-24 | ||
CN2008100007607A CN101239074B (zh) | 2007-01-24 | 2008-01-16 | 海狗油在制备治疗性功能障碍药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101239074A CN101239074A (zh) | 2008-08-13 |
CN101239074B true CN101239074B (zh) | 2010-11-24 |
Family
ID=39931087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100007607A Expired - Fee Related CN101239074B (zh) | 2007-01-24 | 2008-01-16 | 海狗油在制备治疗性功能障碍药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101239074B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012103685A1 (en) * | 2011-02-01 | 2012-08-09 | Nippon Suisan Kaisha, Ltd. | Sexual function improving agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410076A (zh) * | 2001-09-30 | 2003-04-16 | 中国药品生物制品检定所 | 海狗油作为制备治前列腺增生的药的应用 |
-
2008
- 2008-01-16 CN CN2008100007607A patent/CN101239074B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410076A (zh) * | 2001-09-30 | 2003-04-16 | 中国药品生物制品检定所 | 海狗油作为制备治前列腺增生的药的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101239074A (zh) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2440127C2 (ru) | Лекарственные формы, полезные для лечения мужской и женской импотенции | |
AU2003232248B8 (en) | Formulations useful in the treatment of male and female impotence | |
JP2019537628A (ja) | 併用療法 | |
CN101239074B (zh) | 海狗油在制备治疗性功能障碍药物中的应用 | |
CN102423335A (zh) | 一种治疗阳痿、早泄的药物组合物及其制备方法 | |
CN116173177A (zh) | 一种持续改善男性性功能的药物组合物及制备方法 | |
CN102631397B (zh) | 一种改善脑部血液循环的中药组合物及其制备方法 | |
JP4864259B2 (ja) | 性機能障害および血管収縮に関する疾患の予防および治療におけるイカリンの使用 | |
CN101036767B (zh) | 一种改善性功能障碍的组合植物乳液制品及制备方法 | |
CN1907335A (zh) | 一种用于治疗鼻渊的药物组合物及其制备方法 | |
CN114129652A (zh) | 一种具有提高男性性功能作用的中药复方组合物及其应用 | |
CN103169863B (zh) | 一种治疗便秘的药物及其制备方法 | |
US20210113643A1 (en) | A composition for preventing or treating obesity comprising natural mixture extracts | |
CN112843143A (zh) | 治疗便秘型肠易激综合征的中药组合物及其药剂和应用 | |
CN101642502A (zh) | 雄蛾壮阳复方制剂配方及其制造工艺 | |
CN110279734A (zh) | 一种当归精油的应用 | |
CN101081256A (zh) | 一种对眼部疾病具有很好治疗作用的药物 | |
CN104645297A (zh) | 一种温宫助孕的中药组合物及其制剂制备方法 | |
CN113694165A (zh) | 一种复方河豚肝油组合物及其制备方法与应用 | |
KR102129412B1 (ko) | 전립선 비대증 예방, 개선 또는 치료용 조성물 | |
CN1358530A (zh) | 一种治疗肝胆结石的溶石性药物及制备方法 | |
CN1092661A (zh) | 一种治疗艾滋病的药物 | |
TWI421086B (zh) | 治療或減緩發炎性腸病的醫藥組合物 | |
CN104922127B (zh) | 式2化合物在制备治疗和/或预防偏头痛及其并发症的药物中的用途 | |
RU2519226C1 (ru) | Средство для профилактики и лечения андрологических заболеваний и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160815 Address after: 250002, Shandong, Ji'nan Province Shun Shun Road No. 28, Shun Geng Village, Hong Shun court 4 Patentee after: Shandong sun tree Bioengineering Co., Ltd. Address before: Anhui province Hefei city two Street Garden Building 5, room 106, Bi rain Patentee before: Zhang Yixing |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 250000 Shandong city of Ji'nan Province in eastern Pingyin Industrial Park East Park Patentee after: Shandong Tai Yang tree Biological Engineering Co., Ltd. Address before: 250002, Shandong, Ji'nan Province Shun Shun Road No. 28, Shun Geng Village, Hong Shun court 4 Patentee before: Shandong sun tree Bioengineering Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20200116 |
|
CF01 | Termination of patent right due to non-payment of annual fee |